Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Growth 2025-2031
Product Code: 1466839
Industry: Pharma & Healthcare
Published: Apr 10,2025
Pages: 143
Delivery Time: 2-3 business days
Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Growth 2025-2031
Product Code: 1466839
Industry: Pharma & Healthcare
Published: Apr 10,2025
Pages: 143
Delivery Time: 2-3 business days
Select A Format
Single User License
USD3660
Multi Users License
USD5490
Corporate Users License
USD7320
Buy Now
Add To Cart
Or More Options：
PDF Download
Sample Request
Custom Request
Description
The global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market size is predicted to grow from US$ 5071 million in 2025 to US$ 6668 million in 2031; it is expected to grow at a CAGR of 4.7% from 2025 to 2031.
Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection is such a human immunoglobulin for intravenous injection that is made from healthy plasma by cold ethanal protein fractionation and purification, eliminating anticomplementary activity, both through eliminating and deactivating the virus. It contains a proper quantity of stabilizer, and contains no preservatives or antibiotics.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Industry Forecast” looks at past sales and reviews total world Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection sales in 2024, providing a comprehensive analysis by region and market sector of projected Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection sales for 2025 through 2031. With Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection industry.
This Insight Report provides a comprehensive analysis of the global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
1.25g
2.5g
5g
Others
Segmentation by Application:
Hospitals
Clinics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Takeda Pharmaceutical
Baxter International Inc.
CSL Behring
Bayer AG
Grifols, S.A.
Octapharma AG
Taibang Biologic Group
Pacific Shuanglin Bio-pharmacy
Shenzhen Weiguang Biological Products
Nanjing Pharmacare Co.,Ltd
Shanghai RAAS
Harbin Pacific Biopharmaceutical
Hualan Biological Engineering Inc.
China Biologic Products, Inc.
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
Boya Bio-Pharmaceutical Group Co., Ltd.
ADMA Biologics, Inc.
Sinopharm Group Co., Ltd.
Key Questions Addressed in this Report
What is the 10-year outlook for the global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market?
What factors are driving Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection market opportunities vary by end market size?
How does Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection break out by Type, by Application?
Table Of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection by Country/Region, 2020, 2024 & 2031
2.2 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Segment by Type
2.2.1 1.25g
2.2.2 2.5g
2.2.3 5g
2.2.4 Others
2.3 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type
2.3.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Type (2020-2025)
2.3.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue and Market Share by Type (2020-2025)
2.3.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sale Price by Type (2020-2025)
2.4 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Others
2.5 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application
2.5.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sale Market Share by Application (2020-2025)
2.5.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue and Market Share by Application (2020-2025)
2.5.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Breakdown Data by Company
3.1.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Annual Sales by Company (2020-2025)
3.1.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Company (2020-2025)
3.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Annual Revenue by Company (2020-2025)
3.2.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Company (2020-2025)
3.2.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Company (2020-2025)
3.3 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sale Price by Company
3.4 Key Manufacturers Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Location Distribution
3.4.2 Players Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection by Geographic Region
4.1 World Historic Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Geographic Region (2020-2025)
4.1.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size by Country/Region (2020-2025)
4.2.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Annual Sales by Country/Region (2020-2025)
4.2.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Annual Revenue by Country/Region (2020-2025)
4.3 Americas Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Growth
4.4 APAC Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Growth
4.5 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Growth
4.6 Middle East & Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Growth
5 Americas
5.1 Americas Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country
5.1.1 Americas Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2020-2025)
5.1.2 Americas Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Country (2020-2025)
5.2 Americas Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2020-2025)
5.3 Americas Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region
6.1.1 APAC Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region (2020-2025)
6.1.2 APAC Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Region (2020-2025)
6.2 APAC Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2020-2025)
6.3 APAC Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection by Country
7.1.1 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2020-2025)
7.1.2 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Country (2020-2025)
7.2 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2020-2025)
7.3 Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection by Country
8.1.1 Middle East & Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2020-2025)
8.1.2 Middle East & Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Country (2020-2025)
8.2 Middle East & Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2020-2025)
8.3 Middle East & Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection
10.3 Manufacturing Process Analysis of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection
10.4 Industry Chain Structure of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Distributors
11.3 Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Customer
12 World Forecast Review for Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection by Geographic Region
12.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market Size Forecast by Region
12.1.1 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Forecast by Region (2026-2031)
12.1.2 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Forecast by Type (2026-2031)
12.7 Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Takeda Pharmaceutical
13.1.1 Takeda Pharmaceutical Company Information
13.1.2 Takeda Pharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.1.3 Takeda Pharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Takeda Pharmaceutical Main Business Overview
13.1.5 Takeda Pharmaceutical Latest Developments
13.2 Baxter International Inc.
13.2.1 Baxter International Inc. Company Information
13.2.2 Baxter International Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.2.3 Baxter International Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Baxter International Inc. Main Business Overview
13.2.5 Baxter International Inc. Latest Developments
13.3 CSL Behring
13.3.1 CSL Behring Company Information
13.3.2 CSL Behring Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.3.3 CSL Behring Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 CSL Behring Main Business Overview
13.3.5 CSL Behring Latest Developments
13.4 Bayer AG
13.4.1 Bayer AG Company Information
13.4.2 Bayer AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.4.3 Bayer AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Bayer AG Main Business Overview
13.4.5 Bayer AG Latest Developments
13.5 Grifols, S.A.
13.5.1 Grifols, S.A. Company Information
13.5.2 Grifols, S.A. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.5.3 Grifols, S.A. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Grifols, S.A. Main Business Overview
13.5.5 Grifols, S.A. Latest Developments
13.6 Octapharma AG
13.6.1 Octapharma AG Company Information
13.6.2 Octapharma AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.6.3 Octapharma AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Octapharma AG Main Business Overview
13.6.5 Octapharma AG Latest Developments
13.7 Taibang Biologic Group
13.7.1 Taibang Biologic Group Company Information
13.7.2 Taibang Biologic Group Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.7.3 Taibang Biologic Group Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Taibang Biologic Group Main Business Overview
13.7.5 Taibang Biologic Group Latest Developments
13.8 Pacific Shuanglin Bio-pharmacy
13.8.1 Pacific Shuanglin Bio-pharmacy Company Information
13.8.2 Pacific Shuanglin Bio-pharmacy Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.8.3 Pacific Shuanglin Bio-pharmacy Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Pacific Shuanglin Bio-pharmacy Main Business Overview
13.8.5 Pacific Shuanglin Bio-pharmacy Latest Developments
13.9 Shenzhen Weiguang Biological Products
13.9.1 Shenzhen Weiguang Biological Products Company Information
13.9.2 Shenzhen Weiguang Biological Products Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.9.3 Shenzhen Weiguang Biological Products Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Shenzhen Weiguang Biological Products Main Business Overview
13.9.5 Shenzhen Weiguang Biological Products Latest Developments
13.10 Nanjing Pharmacare Co.,Ltd
13.10.1 Nanjing Pharmacare Co.,Ltd Company Information
13.10.2 Nanjing Pharmacare Co.,Ltd Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.10.3 Nanjing Pharmacare Co.,Ltd Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Nanjing Pharmacare Co.,Ltd Main Business Overview
13.10.5 Nanjing Pharmacare Co.,Ltd Latest Developments
13.11 Shanghai RAAS
13.11.1 Shanghai RAAS Company Information
13.11.2 Shanghai RAAS Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.11.3 Shanghai RAAS Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Shanghai RAAS Main Business Overview
13.11.5 Shanghai RAAS Latest Developments
13.12 Harbin Pacific Biopharmaceutical
13.12.1 Harbin Pacific Biopharmaceutical Company Information
13.12.2 Harbin Pacific Biopharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.12.3 Harbin Pacific Biopharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Harbin Pacific Biopharmaceutical Main Business Overview
13.12.5 Harbin Pacific Biopharmaceutical Latest Developments
13.13 Hualan Biological Engineering Inc.
13.13.1 Hualan Biological Engineering Inc. Company Information
13.13.2 Hualan Biological Engineering Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.13.3 Hualan Biological Engineering Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Hualan Biological Engineering Inc. Main Business Overview
13.13.5 Hualan Biological Engineering Inc. Latest Developments
13.14 China Biologic Products, Inc.
13.14.1 China Biologic Products, Inc. Company Information
13.14.2 China Biologic Products, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.14.3 China Biologic Products, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 China Biologic Products, Inc. Main Business Overview
13.14.5 China Biologic Products, Inc. Latest Developments
13.15 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
13.15.1 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Company Information
13.15.2 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.15.3 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Main Business Overview
13.15.5 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Latest Developments
13.16 Boya Bio-Pharmaceutical Group Co., Ltd.
13.16.1 Boya Bio-Pharmaceutical Group Co., Ltd. Company Information
13.16.2 Boya Bio-Pharmaceutical Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.16.3 Boya Bio-Pharmaceutical Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Boya Bio-Pharmaceutical Group Co., Ltd. Main Business Overview
13.16.5 Boya Bio-Pharmaceutical Group Co., Ltd. Latest Developments
13.17 ADMA Biologics, Inc.
13.17.1 ADMA Biologics, Inc. Company Information
13.17.2 ADMA Biologics, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.17.3 ADMA Biologics, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 ADMA Biologics, Inc. Main Business Overview
13.17.5 ADMA Biologics, Inc. Latest Developments
13.18 Sinopharm Group Co., Ltd.
13.18.1 Sinopharm Group Co., Ltd. Company Information
13.18.2 Sinopharm Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications
13.18.3 Sinopharm Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 Sinopharm Group Co., Ltd. Main Business Overview
13.18.5 Sinopharm Group Co., Ltd. Latest Developments
14 Research Findings and Conclusion
List Of Tables
List of Tables Table 1. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions) Table 2. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions) Table 3. Major Players of 1.25g Table 4. Major Players of 2.5g Table 5. Major Players of 5g Table 6. Major Players of Others Table 7. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2020-2025) & (K Units) Table 8. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Type (2020-2025) Table 9. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Type (2020-2025) & ($ million) Table 10. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Type (2020-2025) Table 11. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sale Price by Type (2020-2025) & (US$/Unit) Table 12. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sale by Application (2020-2025) & (K Units) Table 13. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sale Market Share by Application (2020-2025) Table 14. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Application (2020-2025) & ($ million) Table 15. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application (2020-2025) Table 16. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sale Price by Application (2020-2025) & (US$/Unit) Table 17. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Company (2020-2025) & (K Units) Table 18. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Company (2020-2025) Table 19. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Company (2020-2025) & ($ millions) Table 20. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Company (2020-2025) Table 21. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sale Price by Company (2020-2025) & (US$/Unit) Table 22. Key Manufacturers Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Producing Area Distribution and Sales Area Table 23. Players Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Products Offered Table 24. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) Table 25. New Products and Potential Entrants Table 26. Market M&A Activity & Strategy Table 27. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Geographic Region (2020-2025) & (K Units) Table 28. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share Geographic Region (2020-2025) Table 29. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Geographic Region (2020-2025) & ($ millions) Table 30. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Geographic Region (2020-2025) Table 31. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country/Region (2020-2025) & (K Units) Table 32. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Country/Region (2020-2025) Table 33. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Country/Region (2020-2025) & ($ millions) Table 34. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Country/Region (2020-2025) Table 35. Americas Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2020-2025) & (K Units) Table 36. Americas Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Country (2020-2025) Table 37. Americas Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Country (2020-2025) & ($ millions) Table 38. Americas Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2020-2025) & (K Units) Table 39. Americas Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2020-2025) & (K Units) Table 40. APAC Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Region (2020-2025) & (K Units) Table 41. APAC Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Region (2020-2025) Table 42. APAC Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Region (2020-2025) & ($ millions) Table 43. APAC Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2020-2025) & (K Units) Table 44. APAC Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2020-2025) & (K Units) Table 45. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2020-2025) & (K Units) Table 46. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Country (2020-2025) & ($ millions) Table 47. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2020-2025) & (K Units) Table 48. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2020-2025) & (K Units) Table 49. Middle East & Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Country (2020-2025) & (K Units) Table 50. Middle East & Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Country (2020-2025) Table 51. Middle East & Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Type (2020-2025) & (K Units) Table 52. Middle East & Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Application (2020-2025) & (K Units) Table 53. Key Market Drivers & Growth Opportunities of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Table 54. Key Market Challenges & Risks of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Table 55. Key Industry Trends of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Table 56. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Raw Material Table 57. Key Suppliers of Raw Materials Table 58. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Distributors List Table 59. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Customer List Table 60. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Forecast by Region (2026-2031) & (K Units) Table 61. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Forecast by Region (2026-2031) & ($ millions) Table 62. Americas Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Forecast by Country (2026-2031) & (K Units) Table 63. Americas Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Annual Revenue Forecast by Country (2026-2031) & ($ millions) Table 64. APAC Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Forecast by Region (2026-2031) & (K Units) Table 65. APAC Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Annual Revenue Forecast by Region (2026-2031) & ($ millions) Table 66. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Forecast by Country (2026-2031) & (K Units) Table 67. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Forecast by Country (2026-2031) & ($ millions) Table 68. Middle East & Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Forecast by Country (2026-2031) & (K Units) Table 69. Middle East & Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Forecast by Country (2026-2031) & ($ millions) Table 70. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Forecast by Type (2026-2031) & (K Units) Table 71. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Forecast by Type (2026-2031) & ($ millions) Table 72. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Forecast by Application (2026-2031) & (K Units) Table 73. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Forecast by Application (2026-2031) & ($ millions) Table 74. Takeda Pharmaceutical Basic Information, Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors Table 75. Takeda Pharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications Table 76. Takeda Pharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 77. Takeda Pharmaceutical Main Business Table 78. Takeda Pharmaceutical Latest Developments Table 79. Baxter International Inc. Basic Information, Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors Table 80. Baxter International Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications Table 81. Baxter International Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 82. Baxter International Inc. Main Business Table 83. Baxter International Inc. Latest Developments Table 84. CSL Behring Basic Information, Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors Table 85. CSL Behring Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications Table 86. CSL Behring Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 87. CSL Behring Main Business Table 88. CSL Behring Latest Developments Table 89. Bayer AG Basic Information, Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors Table 90. Bayer AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications Table 91. Bayer AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 92. Bayer AG Main Business Table 93. Bayer AG Latest Developments Table 94. Grifols, S.A. Basic Information, Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors Table 95. Grifols, S.A. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications Table 96. Grifols, S.A. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 97. Grifols, S.A. Main Business Table 98. Grifols, S.A. Latest Developments Table 99. Octapharma AG Basic Information, Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors Table 100. Octapharma AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications Table 101. Octapharma AG Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 102. Octapharma AG Main Business Table 103. Octapharma AG Latest Developments Table 104. Taibang Biologic Group Basic Information, Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors Table 105. Taibang Biologic Group Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications Table 106. Taibang Biologic Group Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 107. Taibang Biologic Group Main Business Table 108. Taibang Biologic Group Latest Developments Table 109. Pacific Shuanglin Bio-pharmacy Basic Information, Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors Table 110. Pacific Shuanglin Bio-pharmacy Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications Table 111. Pacific Shuanglin Bio-pharmacy Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 112. Pacific Shuanglin Bio-pharmacy Main Business Table 113. Pacific Shuanglin Bio-pharmacy Latest Developments Table 114. Shenzhen Weiguang Biological Products Basic Information, Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors Table 115. Shenzhen Weiguang Biological Products Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications Table 116. Shenzhen Weiguang Biological Products Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 117. Shenzhen Weiguang Biological Products Main Business Table 118. Shenzhen Weiguang Biological Products Latest Developments Table 119. Nanjing Pharmacare Co.,Ltd Basic Information, Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors Table 120. Nanjing Pharmacare Co.,Ltd Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications Table 121. Nanjing Pharmacare Co.,Ltd Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 122. Nanjing Pharmacare Co.,Ltd Main Business Table 123. Nanjing Pharmacare Co.,Ltd Latest Developments Table 124. Shanghai RAAS Basic Information, Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors Table 125. Shanghai RAAS Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications Table 126. Shanghai RAAS Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 127. Shanghai RAAS Main Business Table 128. Shanghai RAAS Latest Developments Table 129. Harbin Pacific Biopharmaceutical Basic Information, Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors Table 130. Harbin Pacific Biopharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications Table 131. Harbin Pacific Biopharmaceutical Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 132. Harbin Pacific Biopharmaceutical Main Business Table 133. Harbin Pacific Biopharmaceutical Latest Developments Table 134. Hualan Biological Engineering Inc. Basic Information, Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors Table 135. Hualan Biological Engineering Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications Table 136. Hualan Biological Engineering Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 137. Hualan Biological Engineering Inc. Main Business Table 138. Hualan Biological Engineering Inc. Latest Developments Table 139. China Biologic Products, Inc. Basic Information, Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors Table 140. China Biologic Products, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications Table 141. China Biologic Products, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 142. China Biologic Products, Inc. Main Business Table 143. China Biologic Products, Inc. Latest Developments Table 144. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Basic Information, Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors Table 145. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications Table 146. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 147. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Main Business Table 148. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. Latest Developments Table 149. Boya Bio-Pharmaceutical Group Co., Ltd. Basic Information, Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors Table 150. Boya Bio-Pharmaceutical Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications Table 151. Boya Bio-Pharmaceutical Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 152. Boya Bio-Pharmaceutical Group Co., Ltd. Main Business Table 153. Boya Bio-Pharmaceutical Group Co., Ltd. Latest Developments Table 154. ADMA Biologics, Inc. Basic Information, Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors Table 155. ADMA Biologics, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications Table 156. ADMA Biologics, Inc. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 157. ADMA Biologics, Inc. Main Business Table 158. ADMA Biologics, Inc. Latest Developments Table 159. Sinopharm Group Co., Ltd. Basic Information, Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Manufacturing Base, Sales Area and Its Competitors Table 160. Sinopharm Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Product Portfolios and Specifications Table 161. Sinopharm Group Co., Ltd. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025) Table 162. Sinopharm Group Co., Ltd. Main Business Table 163. Sinopharm Group Co., Ltd. Latest Developments List of Figures Figure 1. Picture of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Figure 2. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Report Years Considered Figure 3. Research Objectives Figure 4. Research Methodology Figure 5. Research Process and Data Source Figure 6. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Growth Rate 2020-2031 (K Units) Figure 7. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth Rate 2020-2031 ($ millions) Figure 8. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Geographic Region (2020, 2024 & 2031) & ($ millions) Figure 9. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Country/Region (2024) Figure 10. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Country/Region (2020, 2024 & 2031) Figure 11. Product Picture of 1.25g Figure 12. Product Picture of 2.5g Figure 13. Product Picture of 5g Figure 14. Product Picture of Others Figure 15. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Type in 2025 Figure 16. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Type (2020-2025) Figure 17. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Consumed in Hospitals Figure 18. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market: Hospitals (2020-2025) & (K Units) Figure 19. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Consumed in Clinics Figure 20. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market: Clinics (2020-2025) & (K Units) Figure 21. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Consumed in Others Figure 22. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Market: Others (2020-2025) & (K Units) Figure 23. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sale Market Share by Application (2024) Figure 24. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application in 2025 Figure 25. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales by Company in 2025 (K Units) Figure 26. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Company in 2025 Figure 27. Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue by Company in 2025 ($ millions) Figure 28. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Company in 2025 Figure 29. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Geographic Region (2020-2025) Figure 30. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Geographic Region in 2025 Figure 31. Americas Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales 2020-2025 (K Units) Figure 32. Americas Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue 2020-2025 ($ millions) Figure 33. APAC Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales 2020-2025 (K Units) Figure 34. APAC Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue 2020-2025 ($ millions) Figure 35. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales 2020-2025 (K Units) Figure 36. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue 2020-2025 ($ millions) Figure 37. Middle East & Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales 2020-2025 (K Units) Figure 38. Middle East & Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue 2020-2025 ($ millions) Figure 39. Americas Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Country in 2025 Figure 40. Americas Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Country (2020-2025) Figure 41. Americas Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Type (2020-2025) Figure 42. Americas Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2020-2025) Figure 43. United States Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 44. Canada Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 45. Mexico Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 46. Brazil Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 47. APAC Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Region in 2025 Figure 48. APAC Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Region (2020-2025) Figure 49. APAC Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Type (2020-2025) Figure 50. APAC Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2020-2025) Figure 51. China Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 52. Japan Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 53. South Korea Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 54. Southeast Asia Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 55. India Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 56. Australia Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 57. China Taiwan Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 58. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Country in 2025 Figure 59. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share by Country (2020-2025) Figure 60. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Type (2020-2025) Figure 61. Europe Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2020-2025) Figure 62. Germany Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 63. France Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 64. UK Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 65. Italy Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 66. Russia Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 67. Middle East & Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Country (2020-2025) Figure 68. Middle East & Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Type (2020-2025) Figure 69. Middle East & Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2020-2025) Figure 70. Egypt Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 71. South Africa Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 72. Israel Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 73. Turkey Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 74. GCC Countries Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Growth 2020-2025 ($ millions) Figure 75. Manufacturing Cost Structure Analysis of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection in 2025 Figure 76. Manufacturing Process Analysis of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Figure 77. Industry Chain Structure of Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Figure 78. Channels of Distribution Figure 79. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Forecast by Region (2026-2031) Figure 80. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share Forecast by Region (2026-2031) Figure 81. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share Forecast by Type (2026-2031) Figure 82. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share Forecast by Type (2026-2031) Figure 83. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Sales Market Share Forecast by Application (2026-2031) Figure 84. Global Lyophilized Human Immunoglobulin (PH4) for Intravenous Injection Revenue Market Share Forecast by Application (2026-2031)
Companies Mentioned
Takeda Pharmaceutical
Baxter International Inc.
CSL Behring
Bayer AG
Grifols, S.A.
Octapharma AG
Taibang Biologic Group
Pacific Shuanglin Bio-pharmacy
Shenzhen Weiguang Biological Products
Nanjing Pharmacare Co.,Ltd
Shanghai RAAS
Harbin Pacific Biopharmaceutical
Hualan Biological Engineering Inc.
China Biologic Products, Inc.
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
Boya Bio-Pharmaceutical Group Co., Ltd.
ADMA Biologics, Inc.
Sinopharm Group Co., Ltd.
Methodology
LP Information presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
Data Sourse
Primary Source
Secondary Source
Players/Suppliers
Journals and Periodicals
Industry Experts
Government Bodies
Distributors/Traders
Annual Reports
Opinion Leaders
Presentations
Front-line Staff
Paid Databases
Marketing Executives
LPI Internal Repository
Data Analysis
Data Synthesis
Data Validation
Information Gathering
Triangulation with Data Models
Collation of Data
Reference Against Proprietary
Estimation of Key Figures
Databases
Analysis of Derived Insights
Corroboration with Industry Experts
Writing And Finishing Report
Qualitative Analysis
Qualitative Analysis
Market drivers
Market size and forecast
Market challenges
Market segmentation
Market trends
Geographical insights
Five forces analysis
Competitive landscape
Have A Question?
Provide comprehensive and accurate analysis and reports according to your exact requirements.
Contact Us
Select A Format
Single User License
USD3660
Multi Users License
USD5490
Corporate Users License
USD7320
Buy Now
Add To Cart
Or More Options：
PDF Download
Sample Request
Custom Request
Jump To Content
Description
Table Of Contents
List Of Tables
Companies Mentioned
Methodology
Have A Question?
Provide comprehensive and accurate analysis and reports according to your exact requirements.
Contact Us
17890 Castleton St. Suite 162 City of Industry, CA 91748 United States
Copyright © 2016-2025 LP Information All Rights Reserved
